Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Efegatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.45 |
| ▸ | F2 | P00734 | 5/20 | 0.55 |
| ▸ | PLG | P00747 | 2/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | XIAP | P98170 | 4/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efegatran SCHEMBL7273879 | 0.99 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL7264662 | 0.99 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL564291 | 0.99 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL635674 | 0.96 | F2 (0.58) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL7412481 | 0.93 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Sulfuric Acid SCHEMBL7264554 | 0.92 | F2 (0.54) | F2PLGPRSS1XIAPOPRM1 | |
| Sulfuric Acid SCHEMBL7265422 | 0.91 | F2 (0.53) | F2PLGPRSS1XIAPOPRM1 | |
| SCHEMBL7446078 | 0.90 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Sulfuric Acid SCHEMBL7270900 | 0.90 | F2 (0.52) | F2PLGPRSS1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL7414568 | 0.90 | F2 (0.55) | F2PLGPRSS1XIAPOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-2459220-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2020-09-09 | — | — | EP | disclosed |
| US-20090238770-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| US-20090203777-A1 | ORGANIC COMPOUNDS | MAAS, JANET CATHERINE (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090181934-A1 | Organic Compounds | NOVARTIS AG | 2009-07-16 | — | — | US | disclosed |
| WO-2009050198-A2 | COMBINATION COMPRISING PURINE DERIVATIVES AND OTHER COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAY DISEASES | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| EP-1962848-A2 | COMBINATIONS OF INDACATEROL DERIVATIVES AND OTHER AGENTS FOR THE TREATMENT OF AIRWAY DISEASES | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| CN-101180059-A | Combinations of indacaterol derivatives with other substances for the treatment of airway diseases | NOVARTIS AG (CH) | 2008-05-14 | — | — | CN | disclosed |
| CN-101160284-A | Organic compounds | NOVARTIS AG NOVARTIS PHARMA GM (CH) | 2008-04-09 | — | — | CN | disclosed |
| EP-1874726-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006128674-A2 | COMBINATIONS OF INDACATEROL DERIVATIVES AND OTHER AGENTS FOR THE TREATMENT OF AIRWAY DISEASES | NOVARTIS AG (CH) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006108643-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238770-A1 | Organic compounds | LTB4R, LTB4R2, LTA4H | OPRM1 160/4885OPRK1 168/4885F2 418/4885 |
| US-20090203777-A1 | ORGANIC COMPOUNDS | CFTR, OTC, ASIC1 | OPRM1 204/4885OPRK1 414/4885F2 2423/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | OPRM1 3092/4885OPRK1 3012/4885F2 1990/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | OPRM1 2601/4885OPRK1 2108/4885F2 2824/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | OPRM1 3092/4885OPRK1 3012/4885F2 1990/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | OPRM1 2601/4885OPRK1 2108/4885F2 2824/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | OPRM1 2778/4885OPRK1 3404/4885F2 4510/4885 |
| US-20090181934-A1 | Organic Compounds | LTB4R2, LTA4H, LTB4R | OPRM1 268/4885OPRK1 249/4885F2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.